332 related articles for article (PubMed ID: 18457460)
41. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Chan FKL; Ching JYL; Tse YK; Lam K; Wong GLH; Ng SC; Lee V; Au KWL; Cheong PK; Suen BY; Chan H; Kee KM; Lo A; Wong VWS; Wu JCY; Kyaw MH
Lancet; 2017 Jun; 389(10087):2375-2382. PubMed ID: 28410791
[TBL] [Abstract][Full Text] [Related]
42. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Langtry HD; Wilde MI
Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
[TBL] [Abstract][Full Text] [Related]
43. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries.
Mo C; Sun G; Lu ML; Zhang L; Wang YZ; Sun X; Yang YS
World J Gastroenterol; 2015 May; 21(17):5382-92. PubMed ID: 25954113
[TBL] [Abstract][Full Text] [Related]
44. Lansoprazole: an update of its place in the management of acid-related disorders.
Matheson AJ; Jarvis B
Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
[TBL] [Abstract][Full Text] [Related]
45. Proton Pump Inhibitor-Related Gastric Mucosal Changes.
Kim GH
Gut Liver; 2021 Sep; 15(5):646-652. PubMed ID: 32327613
[TBL] [Abstract][Full Text] [Related]
46. Proton Pump Inhibitors: What the Internist Needs to Know.
Spechler SJ
Med Clin North Am; 2019 Jan; 103(1):1-14. PubMed ID: 30466666
[TBL] [Abstract][Full Text] [Related]
47. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
48. Influence of proton pump inhibitor use in gastrointestinal polyps.
Hsu WH; Wu IC; Kuo CH; Su YC; Lu CY; Kuo FC; Jan CM; Wang WM; Wu DC; Yu FJ
Kaohsiung J Med Sci; 2010 Feb; 26(2):76-83. PubMed ID: 20123595
[TBL] [Abstract][Full Text] [Related]
49. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.
Scally B; Emberson JR; Spata E; Reith C; Davies K; Halls H; Holland L; Wilson K; Bhala N; Hawkey C; Hochberg M; Hunt R; Laine L; Lanas A; Patrono C; Baigent C
Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):231-241. PubMed ID: 29475806
[TBL] [Abstract][Full Text] [Related]
50. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications.
Kedika RR; Souza RF; Spechler SJ
Dig Dis Sci; 2009 Nov; 54(11):2312-7. PubMed ID: 19714466
[TBL] [Abstract][Full Text] [Related]
51. Proton pump inhibitors in cirrhosis: tradition or evidence based practice?
Lodato F; Azzaroli F; Di Girolamo M; Feletti V; Cecinato P; Lisotti A; Festi D; Roda E; Mazzella G
World J Gastroenterol; 2008 May; 14(19):2980-5. PubMed ID: 18494046
[TBL] [Abstract][Full Text] [Related]
52. Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem.
Kanno T; Moayyedi P
Curr Gastroenterol Rep; 2019 Dec; 21(12):65. PubMed ID: 31807948
[TBL] [Abstract][Full Text] [Related]
53. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
Robinson M; Horn J
Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
[TBL] [Abstract][Full Text] [Related]
54. Community-dwelling older adults' awareness of the inappropriate use of proton pump inhibitors.
Rababa M; Rababa'h A
BMC Geriatr; 2020 Oct; 20(1):431. PubMed ID: 33121444
[TBL] [Abstract][Full Text] [Related]
55. Short- and long-term outcomes of surgical management of peptic ulcer complications in the era of proton pump inhibitors.
Hasadia R; Kopelman Y; Olsha O; Alfici R; Ashkenazi I
Eur J Trauma Emerg Surg; 2018 Oct; 44(5):795-801. PubMed ID: 29354867
[TBL] [Abstract][Full Text] [Related]
56. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients.
Paroni Sterbini F; Palladini A; Masucci L; Cannistraci CV; Pastorino R; Ianiro G; Bugli F; Martini C; Ricciardi W; Gasbarrini A; Sanguinetti M; Cammarota G; Posteraro B
Appl Environ Microbiol; 2016 Nov; 82(22):6633-6644. PubMed ID: 27590821
[TBL] [Abstract][Full Text] [Related]
57. Anti-platelet therapy and managing ulcer risk.
Chan FK
J Gastroenterol Hepatol; 2012 Feb; 27(2):195-9. PubMed ID: 22142030
[TBL] [Abstract][Full Text] [Related]
58. Evidence-based clinical practice guidelines for peptic ulcer disease 2015.
Satoh K; Yoshino J; Akamatsu T; Itoh T; Kato M; Kamada T; Takagi A; Chiba T; Nomura S; Mizokami Y; Murakami K; Sakamoto C; Hiraishi H; Ichinose M; Uemura N; Goto H; Joh T; Miwa H; Sugano K; Shimosegawa T
J Gastroenterol; 2016 Mar; 51(3):177-94. PubMed ID: 26879862
[TBL] [Abstract][Full Text] [Related]
59. Acid suppression therapy: where do we go from here?
Scarpignato C; Pelosini I; Di Mario F
Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
[TBL] [Abstract][Full Text] [Related]
60. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing.
Dharmarajan TS
J Am Med Dir Assoc; 2021 Jan; 22(1):15-22. PubMed ID: 33321078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
